Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Suraksha Diagnostic Earnings Call: Key Takeaways

Suraksha Diagnostic reported robust FY26 revenue growth of 23.1% YoY, driven by aggressive regional expansion and a shift toward high-value genomic and specialized radiology testing.

Why this was an Alfa AlertNot a filter event. Revenue growth of 23% was strong but management only confirmed meeting or slightly over-delivering on prior general expectations, not a material 5%+ beat over a specific guided range.
Highlights
Revenue growth23.1% YoY growth driven by volume and premium test mix shift.
MarginsBlended margins dipped to 31.8% due to new center drag.
Demand visibilityStrong demand in Eastern India; expansion into Bihar, Jharkhand, and Tripura.
Management confidenceHigh confidence in regional expansion and technology-led service enhancements.

Growth

Topline grew 23% to ₹3,104M; FY23-FY26 revenue CAGR stands at a strong 17.8% with improving patient yields.

Outlook

Guided 15% revenue growth for FY27; aiming for 100 centers by FY28 with 14 new openings planned.

Risks

EBITDA margins compressed by 200bps YoY to 31.8% due to high pre-operative costs of new centers.

Source

Earnings Call filed with BSE, NSE: SURAKSHA. Summary written with AI assistance from the document.

Read the document ↗

Suraksha Diagnostic Ltd: key numbers

Share price
₹343.30
Market cap
₹1,788 Cr
Revenue (annual)
₹310.4 Cr
Net profit (annual)
₹32.19 Cr
P/E (TTM)
50.0×Sector 57.8×
Promoter holding
49.10%+0.00% QoQ
FII holding
13.47%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Suraksha Diagnostic Ltd

All →
18:27 IST BSE
Annual General Meeting

Suraksha Diagnostic Annual General Meeting

Suraksha Diagnostic Ltd held its 21st AGM on September 22, 2026. Members adopted financial statements, approved a final dividend, and ratified cost auditor remuneration.